StockData

Agenus vs Regenxbio

AGEN and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGEN and RGNX compare

Regenxbio is the larger company, worth 1.7 times as much as Agenus ($478M against $283M).

Agenus grew revenue faster over the last twelve months (30.5% versus 12.0% for Regenxbio).

Regenxbio scores higher on the StockData Score (4 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGENRGNX
Size and price
Market cap$283M$478M
Share price$6.29$7.24
Change, 1 year45.3%−37.1%
Change, 5 years−90.3%−76.6%
Beta (5Y)1.012.63
Employees81371
StockData Score
Total score34 (better)
Valuation score1 (better)0
Growth score22
Performance score01 (better)
Health score01 (better)
Dividend score00
Valuation
P/S2.1× (better)2.7×
P/B–6.7×
EV/EBITDA7.0×–
FCF yield−34.8% (better)−52.2%
Growth
Revenue growth (TTM)30.5% (better)12.0%
Revenue growth, 5Y average5.3% (better)2.0%
Profitability
Gross margin99.5%–
Operating margin27.3% (better)−94.1%
Net margin–−113%
FCF margin−74.2% (better)−143%
Return on equity–−138%
Financial health
Net debt / EBITDA0.28–
Interest coverage0.6× (better)−3.9×
Current ratio0.342.86 (better)
Altman Z-score−16.54−3.88 (better)
Piotroski F-score–4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions31.7%64.2%
Held by insiders6.6%7.6%
Insider net buying, 12 months–$9.6K
Short interest, % of float18.1%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.